FDA rejects expanding label of prostate-shrinking drugs to include cancer prevention. PDF Print
NY Times: The question before the Food and Drug Administration advisory committee on Tuesday was path-breaking: Would it recommend that the labels of two drugs be changed to say that they can reduce a man’s risk of getting prostate cancer?

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.